Company Prepares for US Commercial Launch PRAIRIE VILLAGE, Kan., March 22, 2022 /PRNewswire/ — Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced it received US Food and Drug Administration (FDA) clearance for its Solus Gold Embolization Device, a next-generation product for peripheral vascular […]
Other News
Eko Launches Screening Solution to Help Catch Heart Disease Early
FDA-cleared artificial intelligence (AI) algorithms that detect leading indicators of heart disease are now available to healthcare professionals in the all-new Eko App OAKLAND, Calif., March 22, 2022 /PRNewswire/ — Eko, a digital health company advancing heart and lung disease detection, today announced the launch of its newly-redesigned Eko App, which will transform […]
Medical Device Industry Veteran Christine Horton Named Visura Chief Executive Officer
Horton joins the rapidly growing cardiology company to lead U.S. commercialization efforts MINNEAPOLIS (March 22, 2022) —Visura Technologies, Inc., a medical device company dedicated to delivering state-of-the-art visualization solutions to improve the quality and efficiency of transesophageal echocardiogram (TEE) probe intubation, announced today new leadership as Christine Horton assumes the […]
Impulse Dynamics’ Quality Management System Receives Certification Under European Union Medical Device Regulation
Impulse Dynamics Is Now Among the First US-based Manufacturers of Active Implantable Devices To Receive Certification MARLTON, N.J., March 22, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a company dedicated to innovative treatments for chronic heart failure, is pleased to announce that it has successfully completed the requirements for certification of […]
BioSig Technologies, Inc. Announces $3 Million Financing with Family Office
Westport, CT, March 22, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it entered in a definitive […]
Genomics Testing Companies and Laboratories Combine Efforts to Establish the CardioGenomic Testing Alliance
Coalition aims to raise awareness and utilization of cardiogenomic testing to improve patient outcomes. WASHINGTON, March 22, 2022 /PRNewswire/ — Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic […]
AAN Issues Guidance on Preventing Second Stroke in Those with Plaque in Brain Arteries
MINNEAPOLIS, March 21, 2022 /PRNewswire/ — The use of medications and exercise is more beneficial in preventing a second stroke in people with intracranial atherosclerosis than placing a stent in the blood vessel, according to a new practice advisory issued by the American Academy of Neurology (AAN). The practice advisory is published in the March 21, […]
BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure
New Procedure Reimbursement Code Expected to Enhance Study Performance for Clinical Centers Participating in the CardiAMP Cell Therapy Heart Failure Trial and the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial SUNNYVALE, Calif., March 22, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment […]
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Successfully completed all testing; plan to re-submit FUROSCIX® NDA by April 15, 2022 Commercial preparedness activities ramping up to support anticipated Q4 2022 launch of FUROSCIX, if approved Presented key FREEDOM-HF secondary endpoint data at the Cardiovascular Research Foundation Technology and Heart Failure Therapeutics Conference 2022 Ended Q4 with cash, cash […]
CinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. named Chief Medical Officer Conference call and live webcast today at 8:30 AM […]



